MedTrace Logo

OEA for Targeting Lipid Metabolism in GWI

NCT05252949 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-08-08

No results posted yet for this study

Summary

The study is a single site, randomized, double-blind, placebo-controlled study with an open label extension to evaluate the effects of Oleoylethanolamine (OEA) on blood lipid and immune biomarkers in participants with Gulf War Illness (GWI).

Conditions

  • Gulf War Illness

Interventions

DIETARY_SUPPLEMENT

Oleoylethanolamide (OEA)

Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.

DIETARY_SUPPLEMENT

Placebo

Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Roskamp Institute Inc.

    lead OTHER

Principal Investigators

  • Laila Abdullah, PhD · The Roskamp Institute

  • Michael Hoffmann, MD · The Roskamp Institute

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-10
Primary Completion
2024-09-30
Completion
2025-01-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05252949 on ClinicalTrials.gov